Atara biotherapeutics announces primary analysis data from phase 2 embold clinical trial of ata188 in non-active progressive multiple sclerosis

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its phase 2 embold study of ata188 in non-active progressive multiple sclerosis (pms). the study did not meet the primary endpoint of confirmed disability improvement (cdi) by exp.
ATRA Ratings Summary
ATRA Quant Ranking